Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
NCT06356155Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, pembrolizumab in upper tract urothelial carcinoma (UTUC), sponsored by University of Michigan Rogel Cancer Center. Started Jul 2025; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06356155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356155.